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Summary.-The metabolism of(2-14C) +(3',5',7,9-3H) folic acid was studied in normal
rats, tumour-bearing rats and rats treated with methotrexate (MTX). The experi-
ments were designed to investigate changes in the catabolism of folate. The break-
down of folate to scission products was again demonstrated to be a normal
phenomenon. Catabolites excreted included p-acetamidobenzoate, p-acetamido-
benzoyl-L-glutamate, 3H20, urea and a number of pterins. The catabolic process
was decreased in the presence of a tumour and increased by the administration of
MTX. MTX also led to the excretion of 4 additional radioactive pterins not found in
normal urine. The possible mechanisms of folate breakdown are discussed with
reference to the point of action of MTX.
IN RECENT YEARS there have been
several reports ofscission products appear-
ing in urine as a result of folate degrada-
tion. p-Acetamidobenzoate (Connor et al.,
1979) and p-acetamidobenzoyl-L-gluta-
mate (Murphy et al., 1976) have been
identified as catabolites of 3H folate
tracers; pterin and isoxanthopterin have
been detected after folic acid administra-
tion (Fukushima & Shiota, 1972; Krum-
dieck et al., 1978) and Pheasant & Blair
(1979) reported an unidentified pteridine
as a metabolite of 3H- and 14C-folic acid.
A number of studies suggest that the
pattern of folate coenzymes in malignant
or normal rapidly dividing tissues is
different from that of resting tissues
(Sotobayashi et al., 1966; Barbiroli et al.,
1975) and Stea et al. (1978) have claimed
that tumour cells in culture produce 6-
hydroxymethylpterin as a specific catabo-
lite offolic acid. Folate metabolism in vivo
is known to be affected by the presence of
a tumour; preliminary studies suggest
that the catabolism of folate may be
depressed (Barford & Blair, 1978; Saleh
et al., 1980).
Methotrexate (MTX) is a folate an-
tagonist which is used in cancer chemo-
therapy. It is a potent inhibitor ofdihydro-
folate reductase (EC.1.5.1.3, DHFR)
(Bertino et al., 1964) and is presumed to
act by inhibiting this enzyme. However,
the in vivo situation is complex, and a
number of interacting mechanisms may
be involved in MTX cytotoxicity (Gold-
man, 1977). The drug also inhibits other
folate-dependent enzymes (e.g. thymidy-
late synthetase (EC.2.1.1.45) (Borsa &
Whitmore, 1969) albeit at higher concen-
tration) and acts on dihydropteridine
reductase (EC.1.6.99.10) (Craine et al.,
1972) and Barford et al., 1980) have
presented evidence that DHFR is not the
sole target of MTX methotrexate in vivo.
The major tissue folate derivatives are
polyglutamyl conjugates (Shin et al.,
1972, 1974; Connor & Blair, 1980) and it
appears likely that these derivatives
function as coenzymes (Rowe, 1978).
Previous studies have largely been con-
cerned with the effect of MTX on the
metabolism of radiolabelled folate mono-
glutamates. Administration of MTX, with
or before folic acid, causes excretion of
large amounts of unchanged folic acid,FOLATE CATABOLISM AND MTX
with little or no radio-label incorporated
into the folate pool (Barford et al., 1980).
Effects on the normal tissue folates are
therefore difficult to establish. The present
study compares the metabolism of a
mixture of 2-14C-folic acid and 3',5',7,9-
3H-folic acid in normal rats, in rats
treated with MTX and in tumour-bearing
rats, the experiments involving MTX
being designed to study its effect on folate
polyglutamate metabolism, particularly
their breakdown.
MATERIALS AND METHODS
Experimental design.-Three groups of
male syngeneic WAB/Not rats were used.
Each group consisted of 15 rats.
Group 1: Control rats (160-240 g body wt).
GroupII: Rats bearing Mc103B sarcoma
(260-320 g).
Group III: Normal rats (190-230 g) treated
with MTX.
All rats received an oral dose ofa mixture of
2-14C- and 3',5',7,9-3H-folic acid (100 pg/kg).
Animals were then housed in metabolism
cages (Jencons Metabowls, Jencons Scientific
Ltd, Hemel Hempstead, Herts) designed for
the separate collection of urine and faeces.
Eighthoursaftertheadministrationoflabelled
folic acid, 5 animals from each group were
killed by cervical dislocation and the remain-
ing animals of Group III were given an oral
dose of MTX (100 mg/kg). Synthesis offolate
polyglutamates in the tissues from labelled
folic acid is complete by this time (Bates et
al., 1980). At 24 h a further 5 animals from
each group were killed and the remainder of
Group III received a second dose of MTX
(100 mg/kg). All remaining animals were
killed 24 h later. Liver, tumour, kidney and
gut were removed for determination ofradio-
active content. Throughout all experiments
animals were allowed food (Heygates Breed-
ing Diet) and water ad libitum.
Animals.-Rats were supplied by Dr M.
Pimm, University of Nottingham. The sar-
coma Mc103B was induced in an adult male
WAB/Not rat by s.c. injection of 1 mg
3-methylcholanthrene (Sigma, London) dis-
solved in 1 ml trioctanoin (Eastman Kodak,
Rochester, N.Y., U.S.A.). A tumour trans-
plant line was established and maintained in
syngeneic male rats by s.c. trocar implant-
ation of fragments of tumour tissue (Pimm et
al., 1980). For this experiment the sarcoma
was implanted s.c. on the right flank and
allowed to grow for 4 weeks.
Collection of urine and faeces.-Urine from
5 rats for each interval was collected into
flasks containing 10 ml of 0-05M sodium
phosphate buffer (pH 7.0) containing 2%°,h
(w/v) sodium ascorbate and 5 mg% (w/v)
dithiothreitol. To prevent light degradation
of folates the flasks were surrounded by
aluminium foil. Collection flasks of urine and
faeces were changed 8, 24 and 48 h after
administration of labelled folic acid.
Preparation of liver and tumour extracts.
Hot extracts of livers and tumours were pre-
pared as described by Barford et al. (1977).
Determination of radioactivity.-Urine
samples and column effluents were counted
as described in Connor et al. (1979). Faeces
and tissue samples were freeze-dried and
ground to give a homogeneous powder;
100mg samples were used to estimate total
radioactivity, as described by Barford et al.
(1978).
Column chromatography.-Sephadex G15
gel filtration and DEAE-cellulose chromato-
graphy (using linear gradients of 0-1 2M
NaCl in 0-05M sodium phosphate buffer, pH
7 0) were performed as described by Barford
et al. (1977).
Paper chromatography was performed as
described by Connor et al. (1979).
Chemical8.-All chemicals used were of
Analargrade or its equivalent. 2-14C-folic acid
(sp. radioact. 58 mCi/mmol) and 3',5',7,9-3H-
folic acid (sp. radioact. 500 mCi/mmol) were
obtained from the Radiochemical Centre,
Amersham, Bucks. p-Acetamidobenzoyl-L-
glutamate was prepared as described in
Baker et al. (1964), 10-formylfolate was
synthesized from folic acid (Blakley, 1959),
5,10-methylene-tetrahydrofolate was pre-
pared by Dr R. Nayyir Mazhir as described
by Osborn et al. (1960), pterin-6-aldehyde-
(Waller et al., 1950) and pterin-6-carboxylic
acid (Zakrewski et al., 1970) were prepared by
Dr M. Connor in this department.
RESULTS
Table I summarizes the recovery of
3H and 14C radioactivity in the urine and
faeces of the 3 groups of animals. More
3H than 14C was excreted in the urine of
all animals, and an excess of 14C over 3H
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TABLE I.-Recovery of 3H and 14C in the urine andfaeces of the 3 groups ofanimals given
oral doses of a mixture of 2-14C and 3',5',7,9-3H folic acid (100 ,ug/kg). The results are
expressed as the percentage of the dose recovered during the 3 collection periods (mean
+ s.e., n= 5). Group I-Control rats; Group II-Tumour-bearing rats; Group IJI-
Vormal rats treated with methotrexate
0 of dose recovere(d
0-8 h 8-24 h
Group ,- A
No. 3H 14C 3H 14C
24-48 h Total
*3 1
3H 14C 3H 14C
Urine
Group I 19-8+ 2-6 16-7+ 2-1
Group II 12-7 + 2-4 9 9+ 1.9
Group III 14-4+ 1-6 11-7 + 1-6
Faeces
Group I
Group II --
Group ITI
6-1+09 3-8+05
30+0-5 2-1+0-3
13-9 + 1-3 11-4 + 0-8
11-0+0-9 22-1+1-9
3-4+290 9-7 + 5-2
5-3+ 1-8 10-2 + 3 9
30+03 2-1+0-2
12-+0.1 1-0+0-1
70+04 5-6+03
4-8+0-5 6-2+0-9
09+02 10+0-2
0-7+0-4 0-8+0-5
was present in the faeces. No significant
differences were observed in 0-8 h urinary
radioactivity between control animals
(taken as Group 1+111) and tumour-
bearing animals (Group II). In the later
intervals the tumour-bearing rats excreted
significantly less radioactivity in urine
than control rats (Group I) (P < 002 for
TABLE II.-The chromatographic properties
of the various metabolites appearing in
the urine of the 3 groups of rats
Elution position
Sephadex G1S DEAE-cellulose
gel filtration chromato-
(2 x 60 cm) graphy
fraction No. (2 x 40 cm)
Compound* (5ml fractions) [NaCl] (M)
Folic acid 37 0-96
5MeTHF 37 0-67
IOCHOFA 21 0 53
5,10CH2THF 25 0-64
Folate (X) 36 0 70
p-AcBA 36 0 43
p-AcBG 19 0 43
Metabolite A 41 0 40
Metabolite B 54 0-32
Pterin 35 0 30
pterin-6-COOH 30 0-60
Xanthopterin 57 0 57
Metabolite C 42 0-60
3H2O 21 0.0
Urea 21 0.0
* 5Me THF=5-methyltetrahydrofolate;
IOCHOFA = 10-formylfolate;
5,1OCH2THF = 5,10-methylenetetrahydrofolate;
pAcBA =p-acetamidobenzoate;
p-AcBG =p-acetamidobenzoyl-L-glutamate;
pterin-6-COOH =pterin-6-carboxylic acid.
8-24 h; 0 001<P<0 01 for 24-48 h)
whereas MTX increased the radioactivity
appearing in the 8-24 h and 24-48 h
urine samples of the Group III animals
(P < 0-001 for both intervals). These results
reflect differences in the metabolism of
folate polyglutamate derivatives.
Faecal recovery ofradioactivity was also
reduced in Groups II and III but this was
due to non-production of faeces by a
number of rats.
Urinary metabolites
Urine samples were subjected to sequen-
tial chromatography on DEAE-cellulose
and Sephadex G15. This revealed a
complex mixture of 11 metabolites appear-
ing in the urine of control and tumour-
bearing rats, and at least 14 metabolites
were detected in the urine of the Group
III animals after MTX administration.
The chromatographic behaviour of the
various metabolites is given in Table II,
and Tables Ill-V show the relative dis-
tribution of each metabolite appearing in
the various urine samples.
The same metabolites were seen in
urine from rats in Groups I and II,
though in differing amounts. Five intact
folates were excreted; folic acid, 5-
methyltetrahydrofolate, 10-formylfolate
and 5,10-methylenetetrahydrofolate were
identified by co-chromatography with
authentic standards in both column sys-
28-9 22-6
16-9 13-0
35-3 28-7
15-8 28-3
4-3 10-7
6-0 11-0
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TABLE III.-Metabolites present in the urine of the control rats after the administration of
2-14C and 3',5',7,9-3H-folic acid (100 ,ug/kg)
0 dose recovered as each metabolite
0-8 h 8-24 h 24-48 h Total
-A~~~~~~~~~~ A A A
Metabolite* 3H 14C 3H 14C 3H 14C 3H 14C
Folic acid 1-4 1-3 0-1 0-1 trace trace 1-5 1-4
5MeTHF 6-9 6-5 0 9 0-6 0 4 0 4 8-2 7-5
IOCHOFA 5-8 5-1 1-4 0 9 0-6 0 4 7-8 6-4
5,IOCH2THF 0 9 0-8 0-3 0-2 - 1-2 1.0
Folate (X) 0 5 0 4 0 5 0-4
p-AcBA 1-7 1-5 0-6 3-8
p-AcBG 2-0 0 7 1-0 3-7 -
Metabolite At + 1-4 + 0-7 + 0 7 + 2-8
Metabolite B 0-2 1-0 0-1 0 5 0-1 0 3 0 4 1-8
3H20 0 4 0-2 0-3 0-9
Urea 0-6 0-2 0-2 - 10
* See footnote to Table II.
t The positive 3H label associated with Metabolite A could not be estimated.
TABLE IV.-Metabolites present in the urine oftumour-bearing ratsfollowing the adminis-
tration of 2-14C and 3',5',7,9-3H-folic acid (100 ptg/kg)
% dose recovered as each metabolite
0-8 h 8-24 h 24-48 h Total
Metabolite 3H 14C 3H 14C 3H 14C 3H 14C
Folic acid 4-2 3-5 0-4 0 4 trace 0-1 4-6 4 0
5MeTHF 3-2 2-7 0-3 0 3 0-1 0-1 3-6 3-1
IOCHOFA 1-8 1-5 0*4 0-3 2-2 1-8
5,10CH2THF 0-6 0*5 0-6 0.5
Folate (X) 0 7 0 7 0.1 0-1 0-8 0-8
p-AcBA 0 7 0 7 0 3 1-7
p-AcBG 1-3 0 7 0 5 2-5
Metabolite At + 0-6 + 0-6 + 0 5 + 1-7
Metabolite B 0.1 0 4 0-1 0-2 trace 0-1 0-2 0 7
3H2O 0.1 0-2 - 0-2 - 0-5
Urea 0-1 0-1 0-1 0-3
t The positive 3H label associated with Metabolite A could not be estimated.
TABLE V.-Metabolites present in the urine of normal rats after the administration of
2-14C and 3',5',7,9-3H-folic acid (100 ,tg/kg) and MTX (100 mg/kg body wt) after 8 h
and 24 h
% dose recovered as each metabolite
0-8 h 8-24h 24-48 h Total
Metabolite 3H 14C 3H 14C 3H 14C 3H 14C
Folic acid 0 7 0 7 2-0 1-8 0 7 0 9 3-4 3-4
5MeTHF 6-0 5-1 2-6 2-3 0 4 0.5 9 0 7-9
IOCHOFA 5-3 4-2 1-7 1-4 0-6 0 4 7-6 6-0
5,1OCH2THF 0 7 0-6 0 7 0-7 1-4 1-3
p-AcBA 0 5 2-2 - 07 3-4
p-AcBG 0 5 2-9 3 0 6-4
MetaboliteAt + 0 9 + 1-0 + 0 5 + 2-4
Metabolite B 0-1 0 4 0-1 0 7 0-1 0 5 0 3 1-6
Metabolite C 0-1 0-2 0-2 0-5 0 3 0-7
Pterin - 0-1 0 7 trace 0 3 0-1 1-0
Pterin-6-COOHt - + 1-4 + 0 7 + 2-1
Xanthopterin - 0-2 0 7 0-1 0-6 0 3 1-3
3H20 0-2 0-4 0-7 1-3
Urea 0-2 - 0-2 - 0-3 0-7
t The positive 3H label associated with Metabolite A and Pterin-6-COOH could not be estimated.
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COFOLATE CATABOLISM AND MITX
tems (the fifth intact folate (folate X) has
not yet been identified). Tumour-bearing
animals excreted less of the dose as folate
in the urine. Rats in Groups I and II
excreted 6 catabolites: 3 of these were
labelled solely with 3H and were identified
as p-acetamidobenzoate, p-acetamido-
benzoyl-L-glutamate and 3120; one cata-
bolite was labelled solely with 14C, and
may be urea (Connor et al., 1977) and 2
metabolites (A and B) had an increased
14C: 31- ratio and were possibly pteridines.
Excretion of all scission products was
decreased in the tumour-bearing rats.
MTX increased considerably the excre-
tion of folic acid, 5-methyltetrahydro-
folate and a number of catabolites, in
particuilar p-acetamidobenzoyl-L-gluta-
mate. In addition to increasing excretion
of normal catabolites, MTX also led to
the production of 4 additional radioactive
scission products. None of these was
detected in the urine of rats not receiving
MTX and all had 14C :3H ratios suggesting
pteridines. Three of these additional
metabolites were identified as pterin,
pterin-6-carboxylic acid and xanthopterin
by co-chromatography with authentic
standards in both column systems. We
were unable to identifv the fourth metabo-
lite (C).
Liver and tumnour extracts
Chromatography on Sephadex 015 of
supernatants of liver extracts prepared
from the 3 groups ofanimals and oftumour
extracts prepared from Group II gave
similar results. In all cases the major
radioactive peak eluted in the position
of the folate polyglutamates (i.e. close
to the void volume). Small amounts of
single-labelled compounds (including
pterin) were present, but no folate mono-
glutamates couild be detected at any time.
Recovery of radioactivity in tissues
Table VTI shows the radioactivity re-
tained in the tissues of all groups of
animals at various intervals. In control
and tumour-bearing rats the radioactivity
in the liver increased gradually with time,
48
whereas MTX appeared to cause a fall
in hepatic radioactivity. Considerable
amounts of radioactivity were present in
the tumour tissue, thus increasing the
proportion of the dose retained in the
tumour-bearing rats.
DISCUSSION
These studies again demonstrate that
considerable catabolism of the folate
molecule into non-folate scission products
is a normal phenomenon. The rate at
which this breakdown occurs could have a
significant effect on the folate status ofthe
animal.
Effect ofa tumour
Tumour-bearing rats excreted less radio-
activity in both the urine and faeces.
Qualitatively this is due to a lowered
excretion of most metabolites in the urine.
Although excretion of unchanged folic
acid was higher than normal, overall
excretion of folates was reduced. This
is probably due to uptake of folate and
formation of polyglutamates by a large
tumour mass. Similar observations have
been reported for human subjects suffering
from malignancies (Saleh et al., 1980).
Catabolism of folate was also decreased
in the tumour-bearing rats. The catabo-
lites appearing after the initial 8 h period
arise principally from the breakdown of
folate polyglutamates, since there was no
evidence of folate monoglutamates in the
tissue extracts. p-Acetamidobenzoyl-L-
glutamate is derived by breakdown of the
tissue polyglutamates, whereas p-acetami-
dobenzoate is the catabolite of the mono-
glutamate pool (Connor, 1979). The
levels of p-acetamidobenzoyl-L-glutamate
can therefore be used as a measure of the
breakdown oftissue polyglutamate. Excre-
tion of this compound in the urine is
decreased in the tumour-bearing animals.
This observation is particularly striking
if the increased radioactivity in the
tissues of the tumour-bearing animals is
taken into account. The larger amounts
of radiolabelled polyglutamates would be
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expected to lead
tion ofradio-labe
L-glutamate, ifti
unaltered, wher4
activity found in
excreted as p-a
mate by the t
compared to 6*9'
VII).
TABLE VII.-Ex
folate polyglut
given as the p
activity at 8 h
8-48hperiod
0/
ti
fc
Animal group
Normal (I)
Tumour-
bearing (II)
MTX-
treated (III)
Breakdown of
probably proceei
of a labile folE
through the norn
Tumour cells arE
reducing conditic
are reflected in ir
ratios (Weber e
et al., 1970). 1
lactate by a tun
creased lactate i
may affect other
common in so]
tumours. The (
folate in the pres
due to the sta
folate derivative
conditions prevai
Effect ofmethotre,
The administr
the urinary ex(
The increased e)
5-methyltetrahy(
after MTX admi]
displacement of
to an increased produc- ing binding proteins, and/or to the inhibi-
blled p-acetamidobenzoyl- tion of uptake of folates into cells (Gold-
he catabolic rateremained man, 1971). MTX also increased the
eas 4.4% of the radio- catabolism of folate, which is seen as an
the tissues after 8 h was increase in urinary catabolites, particu-
,cetamidobenzoyl-L-gluta- larly p-acetamidobenzoyl-L-glutamate
tumour-bearing animals, (28% ofthe activity retained in the tissues
>% for the controls (Table after 8 h, Table VII) and a corresponding
fall in the radioactivity in the liver. The
detection of additional catabolites in the
cretion of the catabolite of urine suggests that an abnormal route of
(amates. The results are breakdown also occurs.
oercentage of tissue radio- The labile folate derivative which under-
excreted as pAcBG in the goes scission has not yet been identified,
but tetrahydrofolate and dihydrofolate
3 of % derivatives are likely candidates, because
3H of retained of their inherent chemical instability. he dose radio-
)und in % 3H dose activity Inhibition of dihydrofolate reductase by
tissues excreted excreted MTX would lead to a build-up of dihydro-
at 8 h as PAcBG as pAcBG folate polyglutamates. Chemical oxidation 24-5 1-7 6-9 ofdihydrofolate gives folic acid, formalde-
27-4 1-2 4-5 hyde, p-aminobenzoyl-L-glutamate, di-
hydroxanthopterin and 7,8-dihydropterin-
21-1 5 9 28-0 6-carboxaldehyde (Chippel & Scrimgeour,
1970). The dihydro derivatives are likely
the folate molecule most to oxidize further, giving xanthopterin
ds by oxidative scission and pterin-6-carboxylic acid respectively.
ate derivative produced Thus inhibition ofdihydrofolate reductase,
mal metabolic pathways. leading to increased breakdown of di-
e known to exhibit more hydrofolate derivatives, can account for a
rns in their cytosol, which proportion of the increase in p-acetamido-
ncreased lactate/pyruvate benzoyl-L-glutamate excretion and the
7t al., 1971; Williamson appearance of xanthopterin, pterin-6-
Excessive production of carboxylic acid, 3H20 and folic acid in
nour can also lead to in- the urine of rats treated with MTX, but
in the blood, which thus cannot explain the formation of pterin.
tissues. Also, hypoxia is Neither is pterin produced by the metabo-
lid animal and human lism in vivo of pterin-6-carboxylic acid
lecreased catabolism of (Pheasant & Pearce, 1981).
3ence of a tumour may be However, oxidation of tetrahydrofolate
tbilization of the labile via quinonoid dihydrofolate gives pterin
3 by the more reducing and xanthopterin as the final products
iling. (Blair and Pearson, 1974). This suggests
that tetrahydrofolate derivatives may be
xate involved in the catabolic process. Thus the
-ation of MTX increased fragments found in urine after MTX
cretion of radioactivity. administration are only consistent with
Keretion of folic acid and the breakdown of both tetrahydrofolate
drofolate immediately and dihydrofolate polyglutamates in the
nistration could be due to tissues.
the folates from circulat- Dihydropteridine reductase has been
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shown to use quinonoid dihydrofolate as a
substrate (Lind, 1972) and Pollock &
Kaufman (1978) have suggested that this
enzyme may act in the maintenance ofthe
reduced folates. MTX inhibits dihydro-
pteridine reductase with a K1 of 3-8 x
10-5M (Craine et al., 1972) and this could
cause increased folate breakdown from
tetrahydrofolate via quinonoid dihydro-
folate. The effect of MTX on serum bio-
pterin derivatives (Leeming et al., 1976)
suggests that such inhibition of dihydro-
pteridine reductase occurs in vivo. The
appearance of pterin in the urine after
MTX administration is further evidence
that dihydropteridine reductase does have
a role in folate metabolism in vivo and
that MTX interferes with this role.
Recently 5,10-methylenetetrahydro-
folate reductase (EC.1.1.1.171) has also
been shown to have dihydropteridine
reductase activity, and to reduce quino-
noid dihydrofolate to tetrahydrofolate
(Mat-thews &Kaufman, 1980). Thisenzyme
is weakly inhibited by MTX (Magnum
etal., 1979).
Thus these studies on the catabolism
of the folate polyglutamates suggest that
dihydrofolate reductase is not the sole
enzyme affected by MTX in vivo. Other
possible target enzymes include dihydro-
pteridine reductase and 5,10-methylene-
tetrahydrofolate reductase. The design
of anti-folate drugs to maximize their
effect on these enzymes could lead to a
more effective chemotherapeutic agent
which depletes the cell of folate by
increasing breakdown. This could be
particularly useful since the catabolic
process seems to be decreased in a tumour.
We are grateful to the Cancer Research Campaign
and the Royal Society for financial support and to
Dr M. Pimm (University of Nottingham) for the
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